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Ceftazidime is a broad spectrum antibiotic administered mainly by the parenteral route, and it is especially 
effective against Pseudomonas aeruginosa. The period of time in which serum levels exceed the Minimum 
Inhibitory Concentration (MIC) is an important pharmacodynamic parameter for its efficacy. One of the 
forms to extend this period is to administer the antibiotic by continuous infusion, after prior dilution in a 
Parenteral Solution (PS). The present work assessed the stability of ceftazidime in 5% glucose PS for 24 
hours, combined or not with aminophylline, through High Performance Liquid Chromatography (HPLC). 
The physicochemical evaluation was accompanied by in vitro antimicrobial activity compared MIC test in 
the 24-hour period. Escherichia coli and Pseudomonas aeruginosa were the microorganisms chosen for 
the MIC comparison. The HPLC analysis confirmed ceftazidime and aminophylline individual stability 
on PS, while the MIC values were slightly higher than the mean described in the literature. When both 
drugs were associated in the same PS, the ceftazidime concentration by HPLC decreased 25% after 24 
hours. Not only did the MIC values show high loss of antibiotic activity within the same period, but also 
altered MIC values immediately after the preparation, which was not detected by HPLC. Our results 
indicate that this drug combination is not compatible, even if used right away, and that PS might not be 
the best vehicle for ceftazidime, emphasizing the importance of the MIC evaluation for drug interactions. 
Uniterms: Drug/interactions. Injectables. Parenteral solutions. Ceftazidime/stability. Aminophylline/
stability. High Performance Liquid Chromatography/quantitative analysis. Minimum inhibitory 
concentration (MIC).
Ceftazidima é um antimicrobiano administrado por via parenteral, que apresenta amplo espectro de ação, 
principalmente contra Pseudomonas aeruginosa. O tempo em que a concentração sérica de ceftazidima 
permanece acima da concentração mínima inibitória (MIC) é um importante parâmetro farmacodinâmico 
para a determinação da eficácia antimicrobiana e pode ser potencializado através da utilização de infusão 
contínua em soluções parenterais (PS). Este artigo visa a avaliar a estabilidade da ceftazidima em solução 
de glicose 5%, na presença e na ausência do fármaco aminofilina, através de cromatografia líquida de 
alta eficiência HPLC e MIC durante o período de 24 horas. Os microorganismos selecionados para a 
determinação do MIC foram Escherichia coli e Pseudomonas aeruginosa. Os ensaios em cromatógrafo 
líquido confirmaram a estabilidade dos fármacos ceftazidima e aminofilina quando são individualmente 
associados em PS, enquanto os valores de MIC ficaram maiores que os valores encontrados na literatura. 
Quando ambos os fármacos foram associados na mesma solução parenteral a concentração de ceftazidima 
obtida por HPLC diminuiu 25% depois de 24 horas. Os valores de MIC mostraram maior decaimento 
da atividade antimicrobiana neste mesmo período e também valores de MIC alterados nas soluções 
preparadas no tempo zero, decaimento este que não foi detectado em HPLC. Os resultados indicaram 
incompatibilidade na associação dos fármacos em PS, enfatizando a importância dos resultados de MIC 
para interações de fármacos.
Unitermos: Fármacos/interação. Injetáveis. Soluções parenterais. Ceftazidima/estabilidade. Aminofilina/
estabilidade. Cromatografia Líquida de Alto Desempenho/análise quantitativa. Concentração Inibitória 
Mínima (MIC).
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INTRODUCTION
The most common route for drug administration in 
hospitals is the parenteral one. Parenteral solutions are 
used as vehicles for drug administration, a procedure that 
might include more than one drug diluted in one solu-
tion. This combination favors drug-drug interactions and 
occasionally results in less effective drugs or undesired 
side effects (Trissel, 2010). Another procedure that gives 
room for drug instability is the extension of the infusion 
period with the same parenteral bag. When an antibiotic 
is the drug to be administered, it may lead to damage 
beyond inefficacy for an individual patient. Suboptimal 
antimicrobial doses can contribute to microbial adaptation 
and survival, which allows contamination of the hospital 
environment with antibiotic-resistant bacteria (Jacobs, 
2003). Therefore, it is essential to evaluate the stability of 
antibiotics under the same conditions used in the hospital, 
in order to guarantee the therapeutic effect and prevent 
microbial resistance. 
Ceftazidime (Figure 1A) is a β-lactam antibiotic 
widely used in hospital care through the parenteral route 
to treat gram-negative infections (Dumartin et al., 2010). 
The antibiotic is highly efficient against Pseudomonas ae-
ruginosa, which is the leading cause of hospital-acquired 
infections (Amyes et al., 1994). Although specific, its 
plasma half-life is short, with an average of 2 hours (El-
Shaboury et al., 2007), considering patients with preserved 
renal function (Dalen et al., 1986). Ceftazidime belongs 
to the third-generation cephalosporin class, which has 
maximum in vivo activity when the concentration is four 
times the Minimum Inhibitory Concentration (MIC) 
(Mouton, Vinks, 1996). Due to short plasma half-lives, 
the bactericidal properties from β-lactam antibiotics are 
dependent on the time that its concentration remains above 
the MIC (Fantin et al., 1994). The maximum ceftazidime 
activity can be sustained over time if: the standard dose is 
increased; it is given more frequently; or it is administered 
by continuous infusion (van Zanten, 2009). Continu-
ous infusion of ceftazidime was proved to be effective 
against gram-negative infections, including resistant P. 
aeruginosa and other multidrug resistant strains (Nicolau 
et al., 2001; Lorente et al., 2007; Moriyama et al., 2009; 
Moriyama et al., 2010). The choice of continuous infusion 
can also decrease the antibiotic daily dose (Nicolau et al., 
1996) and result in better cost-effectiveness (McNabb 
et al., 2001). Nevertheless, it is still controversial which 
dose regimen is the best, due to limited human studies on 
the subject (Mouton, Vinks, 1996; Roberts et al., 2009).
The antimicrobial properties of ceftazidime can be 
associated with the bronchodilator properties of amino-
phylline (Figure 1B), which may improve the treatment 
of patients with respiratory disorders (Pleasants et al., 
1992). Aminophylline is more effective when adminis-
tered to hospitalized patients through continuous infusion 
(Budavari et al., 1996; Hilliard et al., 2000), probably due 
to significant differences in the plasma half-life of theoph-
ylline over time (Kubo et al., 1986). The combination of 
both drugs was reported as stable for up to two hours in 
parenteral solutions (Pleasants et al., 1992). Since most 
hospitals do not submit the drug mixture to a rigorous 
quality control, the association should be carefully studied 
according to its physicochemical and biological properties. 
Based on the presented information, this work aimed to 
evaluate the stability of the ceftazidime-aminophylline 
association in glucose parenteral solution. The physico-
chemical stability evaluation was carried for 24 hours by 
HPLC (High Performance Liquid Chromatography) and 
the antimicrobial activity was analyzed during the same 




Aminophylline (99.8 % Medley, Brazil) and ceftazi-
dime (99.9 % anhydrous base) were used as the secondary 
FIGURE 1 - Molecular structure of ceftazidime (A) and aminophylline (B). A – Ceftazidime: C22H22N6O7S2. B – Aminophylline: 
two molecules of theophylline, C7H8N4O2, for each molecule of ethylenediamine, C2H4(NH2)2.
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standards for HPLC analysis. All glassware used in the 
experiments were previously immersed in a 1 M NaOH 
solution for 24 h, drained and transferred to a 1 M nitric 
acid solution for 6 h. After extensive rinsing and 24 h im-
mersion in purified water (Milli-Q), the equipment was 
autoclaved for 30 min at 121 °C. All plastic materials 
were sterile and disposable. All reagents used were of 
analytical grade.
Drug solutions
Ceftazidime (Glaxo Smithkline, Brazil) was diluted 
(0.1 mg/mL) in a parenteral solution with 5% glucose 
(Aster, Brazil) for the stock solution. The same was made 
for aminophylline (Hypofarma, Brazil) to a final concen-
tration of 24 mg/mL. Stock solutions were made immedi-
ately prior to use at room temperature (25 ºC). The stock 
solutions were then diluted to 320µg/mL for ceftazidime 
and 160 µg/mL for aminophylline in parenteral solution, 
individually or associated with each other (herein called 
“drug mixture”). The chosen dilutions were based on the 
plasma concentrations reported in the literature (Trevor, 
Katzung, Masters, 2001).
Bacterial strains and growth conditions
Escherichia coli ATCC 25922 and Pseudomonas 
aeruginosa ATCC 9721 were used as the biological sen-
sors for antimicrobial activity. E. coli was inoculated in 
Luria Bertani (LB) (DIFCO) broth medium and cultivated 
at 37 ºC/100 rpm/24 hours. P. aeruginosa was inoculated 
in Trypticase Soy Broth (TSB) broth and also cultivated 
at 37 ºC/100 rpm/24 hours.
pH Determination
The pH of all solutions was measured at 25 °C with a 
pHmeter (Accumet AR20, Fisher Scientific, USA) before 
analysis by HPLC and MIC test.
HPLC
Pharmacopeic methods (USP, 2009) of ceftazidime 
and aminophylline were combined in a new method de-
scribed in this item. Reversed-phase HPLC was performed 
on a Shimadzu LC 10 (software LC solution; Shimadzu, 
Japan), using a 250 x 4.6 mm (internal diameter) column 
pre-packed with C18 and 12.7 nm of pore size (Shim-pack 
VP–ODS, Shimadzu, Japan). The parameters applied were 
0.5 mL/min flow at 25 °C and a sample injection volume 
of 20 µL, while the mobile phase consisted of 35% aceto-
nitrile, 2% phosphoric acid 1% (pH 7.0) and water (WFI 
- Water For Injection). Eluted samples were detected at the 
optimum wavelength (Budavari et al., 1996) for ceftazi-
dime (255 nm) and aminophylline (275 nm). This method 
was developed according to the validation guideline from 
the International Conference on Harmonization of Techni-
cal Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) (ICH, 2005). The required assays de-
scribed in the guideline are specificity, linearity and range 
concentration, accuracy, precision and reproducibility. In 
order to access specificity in the presence of degradation 
products, the samples were exposed to 10% H2O2 (2:1, 
v/v) for 1h, followed by HPLC analysis and comparison 
with the untreated samples.
MIC determination
The antimicrobial activity of ceftazidime samples 
was evaluated by MIC test, according to the guideline from 
the Clinical and Laboratory Standards Institute (CSLI) 
(CSLI, 2009). Briefly after the cultivation, both micro-
organisms were adjusted to 106 Colony Forming Units 
(CFU)/mL and distributed in test tubes with two-fold se-
rial dilutions of samples, except for the negative controls. 
Tubes were then incubated for 24 h/37 °C. Bacterial counts 
were made in agar plates cultured with the content of the 
test tubes for 24 hour incubation at 37 °C.
Data analysis
Chromatograms were obtained using the LC Solu-
tion Software (Shimadzu). To confirm the linearity of the 
HPLC method, a regression line was calculated by the 
least-squares method. To check the statistical significance 
of the differences (p) between the mean values compared 
throughout the article, the two-tailed t-test method was 
applied using the Excel® software, where p values below 
0.05 represent statistical significance of the differences 
between two compared means.
RESULTS
pH Determination
The pH values of all solutions were within the ranges 
described in the literature. The observed values did not 
change after 24-hour storage at room temperature. The 
ceftazidime average pH was 6.6, with standard devia-
tion of 0.3 (pH=6.6 ± 0.3). The aminophylline average 
pH=9.5 ± 0.3 and the ceftazidime + aminophylline average 
pH=8.30 ± 0.4.
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HPLC method development and performance
The HPLC method presented no statistical differ-
ences between the retention times for samples and for the 
respective standards (ceftazidime p=0.13 and aminophyl-
line p=0.06). In addition, peroxide degradation products 
did not interfere with non-degraded drug peaks (Figure 
2). Due to both facts, the developed methodology can be 
considered specific. The method was linear for both sub-
stances, with R2 of 0.99 in the 70-130% range. Accuracy 
and precision were also achieved, with standard deviation 
less than 0.1 % of the sample value. There were no inter-
laboratorial assays; the reason why reproducibility was 
not verified.
FIGURE 2 - Specificity of the HPLC method for ceftazidime and aminophylline. A) Chromatograms of ceftazidime (320 μg/mL) and 
aminophylline (160 μg/mL) untreated samples. B) Chromatograms of the same samples treated with hydrogen peroxide. Samples 
were read at 275 nm, the ideal wavelength for aminophylline detection (front chromatogram of A and B), and at 255 nm, the ideal 
wavelength for ceftazidime detection (back chromatogram of A and B). S.I.=Signal intensity, min=minutes (retention time).
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*The reported mean values were collected from three 
independent experiments, using triplicate samples in each of 
them. The highest standard deviation was less than 0.02% of 
the mean concentration value.













* The reported mean values were collected from three 
independent experiments, using triplicate samples in each of 
them. The highest standard deviation was less than 0.02% of 
the mean concentration value.
TABLE III – Antimicrobial activity of ceftazidime diluted in 5% glucose parenteral solution
Strain
MIC ceftazidime (µg/mL)* - (individual solution) MIC ceftazidime (µg/mL) - Drug mixture*
0 h 24 h 0 h 24 h
Escherichia coli 1.0 3.7 15.0 120.0
Pseudomonas aeruginosa 1.9 3.7  7.5  30.0
* The reported mean values were collected from three independent experiments, using triplicate samples in each of them. The 
highest standard deviation was less than 0.01% of the mean concentration value.
Stability of ceftazidime and aminophylline 
solutions by HPLC
Triplicate samples of ceftazidime, aminophylline 
and the drug mixture were diluted in 5% glucose par-
enteral solutions, followed by HPLC analysis at 0, 2, 6 
and 24 h after preparation. Drugs were considered stable 
when concentrations were ≥95 % of the values obtained 
immediately after drug dilution, without mixing (Farina et 
al., 1999). Aminophylline, was stable at all time periods 
evaluated (Table I), as it was previously published, regard-
less of ceftazidime addition.
Ceftazidime was also stable when diluted alone. 
However, its association with aminophylline resulted in 
a 12.5% loss of the antibiotic after the 6 h period (Table 
II). The decrease in concentration doubled at 24 h (25%), 
confirming the instability reported for this association 
(El-Shaboury et al., 2007).
Antimicrobial activity of ceftazidime solutions by 
the MIC test
Ceftazidime, aminophylline and the drug mixture 
were diluted in 5% glucose parenteral solutions, followed 
by MIC determination at 0 and 24 h after preparation 
(Table III). The tested bacteria were E. coli, a standard 
sensitive strain, and P. aeruginosa, the main target patho-
gen for this antibiotic. The observed MIC for ceftazidime 
alone at time zero is within the range found in the litera-
ture, but slightly higher than the available means (Neu, 
Labthavikul, 1982). This MIC value was herein considered 
as the reference value for comparison purposes (1.0 µg/
mL of ceftazidime for E. coli and 1.9 µg/mL for P. aeru-
ginosa). The MIC value for ceftazidime alone increased 
four times for E. coli and two times for P. aeruginosa after 
24 h, showing a decrease of the biological activity. The 
drug mixture revealed negative interactions immediately 
after the preparation, with a MIC value 15 times higher 
than the reference value for E. coli. This effect was less 
prominent in the test with P. aeruginosa, in which the 
MIC was 4 times higher than the reference. The analysis 
after 24 h showed MIC values 120 times higher than the 
reference for E. coli and 15 times higher for P. aeruginosa. 
The aminophylline solution was not bactericidal by itself, 
as expected.
DISCUSSION
The physicochemical stability of ceftazidime has 
been analyzed by HPLC in a variety of solutions. This 
antibiotic was previously reported as stable in 5% glucose 
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solution after 24 hours, although a 5% loss was detected 
(Moriyama, 2009). The same profile was confirmed in 
our results.
The spread of HPLC analysis contrasts with the 
rarity of antimicrobial activity tests applied to ceftazi-
dime stability studies. Our efforts were then directed to 
determine its antimicrobial activity in the same glucose 
parenteral solution. MIC values of ceftazidime that inhibit 
P. aeruginosa growth doubled after 24 hours. Since MIC 
determination is based on a serial 2 fold dilution, the 5% 
antibiotic loss detected by HPLC could double the MIC 
value.
A prominent loss in antimicrobial activity of 
ceftazidime was observed against E. coli, where the MIC 
increased four times after 24 hours. This increment cannot 
be explained by the 5% antibiotic loss detected by HPLC. 
Another group also observed the diminished activity of 
ceftazidime against E. coli when media was enriched 
with glucose (Malouin et al., 1991). They reported that 
the glucose concentration was directly proportional to 
PBP 8 (Penicillin Binding Protein) production by E. coli, 
while it was inversely proportional to the antimicrobial 
antibiotic activity. Ceftazidime exerts its bactericidal ef-
fect by inhibiting the enzymes responsible for cell-wall 
synthesis, especially PBP3, though it has low affinity to 
PBP8 (Malouin et al., 1991; Clairoux et al., 1992). It is 
possible that the augmented BPB8, an enzyme that is not 
efficiently degraded by ceftazidime, allows the bacteria to 
continue wall synthesis and scape from antibiotic interven-
tion. Nevertheless, the mechanism has not been elucidated 
so far and other studies should be carried out in order to 
evaluate the impact of this phenomenon in vivo.
The combination of ceftazidime with aminophylline 
resulted in ceftazidime degradation, which initiated be-
tween 2 and 6 hours after mixture preparation and peaked 
at 24 hours, summing 25% total loss of ceftazidime. Ami-
nophylline is composed by a teophylline-etilenodiamine 
complex that is stable at basic solutions (Ishiguro et al., 
1980), and remained stable when combined with the anti-
biotic. On the other hand, maximum ceftazidime stability 
is achieved within the pH range of 4.5 to 6.5 (Zhou et 
al., 1995), while its hydrolysis is favored in an alkaline 
environment (Vilanova et al., 1993). The basic pH of the 
resulting mixture may by itself explain the significant loss 
of antibiotic concentration. It is unlikely that both drugs 
reacted with each other, mainly because aminophylline 
maintained its physicochemical stability. Accordingly, 
another cephalosporin combined with the same broncho-
dilator showed no pharmacokinetic interactions between 
the two drugs (Szmygin, 1996). The drug mixture in 
glucose parenteral solution was considered by another 
group as stable within a 0-2 h range and unstable within 
a 6 to 24 h range; results which were reproduced by our 
HPLC experiments (El-Shaboury, 2007). However, the 
same drug mixture at 0 hour presented ceftazidime MIC 
increase of 15 and 3.9 fold for E. coli and P. aeruginosa, re-
spectively. The hydrolysis of ceftazidime triggered by the 
basic pH was probably enhanced by the 37 °C maintained 
throughout the MIC tests (Farina et al., 1999). Since the 
human body maintains the same temperature, it is likely 
that degradation continues after drug infusion.
The MIC test proved to be a valuable tool when 
evaluating antibiotics stability in non-standard condi-
tions. The biological method makes it possible to detect 
antibiotic and vehicle changes in the presence of the target 
microorganisms and nutritional factors at body tempera-
ture. It is important to highlight that MIC was used in our 
experiments to evaluate the loss of antibiotic activity when 
compared to an initial solution, but not with a biological 
reference standard. Therefore, further work is required 
to include MIC as a routine test for stability, including 
antibiotic potency determination and method validation.
The previously reported incompatibility of ceftazi-
dime and aminophylline was confirmed by our data. In 
addition, it was demonstrated that the combination is not 
stable even immediately after the preparation, due to loss 
of antimicrobial activity of ceftazidime. Based on these 
findings, it is not advisable to administer ceftazidime 
with aminophylline in the same container or by the same 
intravenous set. Results also suggest that glucose paren-
teral solution may not be the best choice for a ceftazidime 
vehicle, especially when a degradation process has already 
been triggered.
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